Table 1 Baseline characteristics of patients undergoing hematopoietic stem cell transplantation (HSCT). This table summarizes demographic data, underlying diseases, conditioning regimens, and donor types for all study participants.

From: Prophylactic infusion of donor derived CMV specific T cells for the prevention of CMV reactivation following allogeneic HSCT

Characteristics

Control group

ATC group

Number of participants

10

10

Recipient age in years, Median (Range)

33 (20–47)

35.5 (18–51)

Donor age in years, Median (Range)

39 (10–55)

34 (19–53)

Recipient gender

Female

4 (40%)

6 (60%)

Donor gender

Female

6 (60%)

7 (60%)

ABO compatibility

Matched

6 (60%)

6 (60%)

Mismatched

4 (40%)

4 (40%)

Background disease

AML

6 (60%)

5 (50%)

ALL

4 (40%)

5(50%)

Remission status pre HSCT

CR1

4 (60%)

6 (60%)

CR >  = 2

6 (40%)

4 (40%)

HSCT type

Haploidentical

7 (70.0%)

7 (70.0%)

Full matched

3 (30.0%)

3 (30.0%)

CD3*106, mean (± SD)

333.55 (± 88.02)

250.13 (± 76.50)

CD34*106, mean (± SD)

8.64 (± 1.66)

6.54 (± 1.54)

Donor relation

Sibling

7 (70.0%)

10 (100%)

Parents

1 (10%)

0 (0%)

Offspring

2 (20)

0 (0%)

Disease risk index

Low/Intermediate

3 (30%)

3 (30.0%)

Intermediate/High

7 (70%)

7(70%)

  1. Data are presented as frequency (%), Median (Range), and mean (± standard deviation).
  2. ATC, Adaptive T Cell; HSCT, Hematopoietic Stem Cell Transplantation; CR, Complete Response; ALL, Acute Lymphoblastic Leukemia; AML, Acute Myeloid Leukemia; SD, standard deviation.